Combination oral contraceptive pills offer BMI, lipid benefit in PCOS

  • Li L & al.
  • BMC Womens Health
  • 27/02/2020

  • Elisabeth Aron, MD, MPH, FACOG
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • The combination of 3 mg drospirenone (DRSP) and 20 μg ethinyl estradiol (EE) has favorable metabolic and hormonal effects in people with PCOS.

Why this matters

  • DRSP has antimineralocorticoid and antiandrogenic activities.
  • The prevalence of PCOS among reproductive-age women is 6%-10%.

Key results

  • Improvements in metabolic and hormonal profile after 3 months of DRSP/EE tablets:
    • Decreased BMI (P<.001 waist-hip ratio>
    • Decreased testosterone (P<.001>
    • Increased high-density lipoprotein-cholesterol (P<.001>
    • Decreased ovarian volume (P<.05>
  • No change in blood glucose levels or insulin resistance.
  • 42.14% of patients reported discomfort including gastrointestinal disorder, dizziness, headache, breast swelling, or irregular bleeding.

Study design

  • Single-center, prospective, observational study.
  • Patients with PCOS were prescribed once daily DRSP/EE tablets (n=140).
  • Anthropometric measurements, sex hormones, glucolipid metabolic index, ovarian volume, and adverse effects were recorded at baseline and after 3 months of treatment.
  • Funding: Science and Technology Planning Project of Guangdong Province; Key Project of Guangdong Provincial Administration of Traditional Chinese Medicine; Guangzhou Municipal Science and Technology Innovation Council.

Limitations

  • Small sample size.
  • Retrospective study.
  • Single center, so results may not be generalizable.
Continuando a navigare sul nostro sito web, l'utente acconsente all'uso dei cookies da parte nostra ai fini di analizzare l'uso del sito e per visualizzare ed inviarvi contenuti mirati, comprese offerte e promozioni. Cliccare qui per ulteriori informazioni o per disabilitare le impostazioni dei cookies. Scopri di più - Gestire le Impostazioni
Univadis will update its Terms of Use and Privacy Policy on January 12, 2016. Please contact if you have any questions about these changes. If you continue to use Univadis after January 12, 2016 the new Terms of Use and Privacy Policy will apply. By your continued use of Univadis, you accept and agree to these terms and policies.
Univadis has updated its Terms of Use and Privacy Policy. Please contact if you have any questions about these changes. By your continued use of Univadis, you accept and agree to these terms and policies.